Drug intelligence / Profile preview

Lactobacillus delbrueckii subsp. lactis CKDB001

Development stage: Phase 1
Lead developer: CKD Bio
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

CKDB001 (*Lactobacillus delbrueckii* subsp. *lactis* CKDB001) is a probiotic strain developed for the treatment of cognitive impairment and neurodegenerative diseases such as Alzheimer's disease. As a live biotherapeutic, it functions through the gut-brain axis to modulate the intestinal microbiome and increase the production of neuroprotective metabolites, including tryptophan-derived indoles and short-chain fatty acids. Its neuroprotective mechanisms include the downregulation of hippocampal glycogen synthase kinase-3 (GSK-3) signaling, reduction of tau phosphorylation, and restoration of acetylcholinesterase (AChE) activity. Additionally, CKDB001 enhances gut barrier integrity by upregulating tight-junction proteins, which may help mitigate the systemic inflammation associated with cognitive decline. In preclinical models, its efficacy in improving spatial working memory has been shown to be comparable to that of donepezil.

Other names: Lactobacillus delbrueckii subsp. lactis CKDB001

Targets

AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on Lactobacillus delbrueckii subsp. lactis CKDB001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactobacillus delbrueckii subsp. lactis CKDB001.

Explore the full profile